NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free IMGN Stock Alerts $31.23 0.00 (0.00%) (As of 02/26/2024) Add Compare Share Share Today's Range$31.23▼$31.2350-Day Range$29.26▼$31.2352-Week Range$3.61▼$31.25Volume40 shsAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice Target$25.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ImmunoGen alerts: Email Address ImmunoGen MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside17.5% Downside$25.77 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.25Based on 3 Articles This WeekInsider TradingSelling Shares$5.56 M Sold Last QuarterProj. Earnings Growth362.50%From $0.08 to $0.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 starsMedical Sector792nd out of 938 stocksBiotechnology Industry35th out of 47 stocks 1.1 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.77, ImmunoGen has a forecasted downside of 17.5% from its current price of $31.23.Amount of Analyst CoverageImmunoGen has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IMGN. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 65.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.86. Previous Next 1.8 News and Social Media Coverage News SentimentImmunoGen has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ImmunoGen this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for IMGN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows6 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,562,450.00 in company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About ImmunoGen Stock (NASDAQ:IMGN)ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Read More IMGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMGN Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Coverage Initiated at StockNews.comMarch 23, 2024 | americanbankingnews.comImmunoGen, Inc. (NASDAQ:IMGN) Receives Consensus Recommendation of "Hold" from AnalystsMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 22, 2024 | marketwatch.comAbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen DealFebruary 21, 2024 | msn.comAbbVie plans to offer senior notes to fund Immunogen, Cerevel dealsFebruary 19, 2024 | ca.finance.yahoo.comCERE Aug 2024 30.000 callFebruary 12, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on ImmunoGen (IMGN)February 12, 2024 | msn.comAbbVie revises Q1 earnings outlook as ImmunoGen deal closesMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 9, 2024 | finance.yahoo.comIs ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?February 9, 2024 | seekingalpha.comFinal Countdown: AbbVie's Imminent Closure With ImmunoGen And What It MeansFebruary 9, 2024 | msn.comImmunoGen Set to Merge with AbbVie, Awaiting Final ApprovalFebruary 9, 2024 | finance.yahoo.comImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?February 2, 2024 | finance.yahoo.comImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 2, 2024 | finance.yahoo.comImmunoGen, Inc. (IMGN) Interactive Stock Chart - Yahoo FinanceJanuary 9, 2024 | finance.yahoo.comHow ImmunoGen (IMGN) Stock Stands Out in a Strong IndustryJanuary 4, 2024 | nasdaq.comIMGN Quantitative Stock AnalysisJanuary 4, 2024 | msn.comAll You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong BuyDecember 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLYDecember 22, 2023 | finance.yahoo.comAre Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?December 19, 2023 | morningstar.comImmunogen Inc IMGNDecember 16, 2023 | msn.comImmunogen (IMGN) Price Target Increased by 35.04% to 31.68December 7, 2023 | reuters.comAbbvie to focus on smaller deals after Cerevel and ImmunoGen buyoutDecember 7, 2023 | finance.yahoo.comAbbVie acquiring Cerevel Therapeutics in $8.7B dealDecember 5, 2023 | msn.comImmunoGen bags priority review for full approval of ovarian cancer drugDecember 5, 2023 | markets.businessinsider.comImmunoGen Receives FDA's Priority Review For ELAHERE In Platinum-Resistant Ovarian CancerDecember 5, 2023 | finance.yahoo.comFDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian CancerSee More Headlines Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Price Target and Rating Average Stock Price Target$25.77 High Stock Price Target$31.26 Low Stock Price Target$16.00 Potential Upside/Downside-17.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio390.38 P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableOptionable Beta1.18 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark Joseph Enyedy (Age 60)President, CEO & Director Comp: $1.28MDr. Michael J. Vasconcelles M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $304.62kMs. Lauren A. White M.B.A. (Age 45)Senior VP & Chief Financial Officer Anabel ChanHead of Investor RelationsMr. Daniel S. Char J.D. (Age 62)Senior VP, Chief Legal Officer & Secretary Ms. Courtney O'KonekSenior Director of Corporate Communications & Investor RelationsMs. Audrey BerganSenior VP & Chief HR OfficerDr. Theresa G. Wingrove (Age 66)Senior Vice President of Regulatory Affairs & Quality Comp: $548.21kMs. Isabel KalofonosSenior VP & Chief Commercial OfficerMore ExecutivesKey CompetitorsRayzeBioNASDAQ:RYZBRoivant SciencesNASDAQ:ROIVViking TherapeuticsNASDAQ:VKTXPenumbraNYSE:PENAscendis Pharma A/SNASDAQ:ASNDView All CompetitorsInsiders & InstitutionsLeo Wealth LLCBought 25,016 shares on 3/14/2024Ownership: 0.009%Vanguard Group Inc.Bought 984,795 shares on 3/11/2024Ownership: 9.565%Wellington Management Group LLPSold 11,304,584 shares on 3/5/2024Ownership: 0.734%Twin Focus Capital Partners LLCSold 32,000 shares on 3/5/2024Ownership: 0.012%Goldman Sachs Group Inc.Sold 49,614 shares on 3/1/2024Ownership: 0.447%View All Insider TransactionsView All Institutional Transactions IMGN Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price target for 2024? 12 brokerages have issued 12-month target prices for ImmunoGen's stock. Their IMGN share price targets range from $16.00 to $31.26. On average, they anticipate the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 17.5%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How have IMGN shares performed in 2024? ImmunoGen's stock was trading at $29.65 at the start of the year. Since then, IMGN stock has increased by 5.3% and is now trading at $31.23. View the best growth stocks for 2024 here. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings data on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.14. The biotechnology company had revenue of $83.20 million for the quarter, compared to analyst estimates of $49.15 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%. The business's quarterly revenue was up 485.9% compared to the same quarter last year. During the same period last year, the business posted ($0.24) EPS. What ETFs hold ImmunoGen's stock? ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), iShares Micro-Cap ETF (IWC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS) and iShares Biotechnology ETF (IBB). What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.56%), Vanguard Group Inc. (9.56%), Norges Bank (2.08%), FIL Ltd (2.01%), Voloridge Investment Management LLC (1.21%) and Northern Trust Corp (0.87%). Insiders that own company stock include Kristine Peterson, Mark J Enyedy, Renee Lentini, Stacy Ann Coen and Theresa Wingrove. View institutional ownership trends. How do I buy shares of ImmunoGen? Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More This page (NASDAQ:IMGN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.